SG Americas Securities
SPRO icon

SG Americas Securities’s Spero Therapeutics SPRO Stock Holding History

SG Americas Securities’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,617
Closed -$195K – 3775
2021
Q3 		$195K Buy
+10,617
New +$170K ﹤0.01% 3251
2020
Q3 		– Sell
-7,858
Closed -$106K – 3393
2020
Q2 		$106K Buy
+7,858
New +$88.2K ﹤0.01% 3336

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

SG Americas Securities's SPRO Position: Q4 2021 in Review

SG Americas Securities sold out of Spero Therapeutics (SPRO) in Q4 2021, closing a stake of 10,617 shares — an estimated $195K sold.

SG Americas Securities first reported a position in SPRO in Q2 2020 and held it in 2 quarters. The position peaked at $195K in Q3 2021. 84 funds tracked by Wall St. Rank hold SPRO as of Q4 2021.

  • SG Americas Securities reported no remaining Spero Therapeutics position as of Q4 2021 after selling out during the quarter.
  • SG Americas Securities sold 10,617 Spero Therapeutics shares in Q4 2021, an estimated $195K.
  • SG Americas Securities first reported a position in Spero Therapeutics in Q2 2020 and held it in 2 quarters.
  • SG Americas Securities's Spero Therapeutics position peaked at $195K in Q3 2021.
  • 84 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2021.

Based on SG Americas Securities's 13F filing for Q4 2021, filed 7 Feb 2022.